Avacta Group Dirección

Dirección controles de criterios 1/4

Actualmente no disponemos de información suficiente sobre el CEO.

Información clave

Chris Coughlin

Chief Executive Officer (CEO)

UK£37.0k

Compensación total

Porcentaje del salario del CEO	n/a
Permanencia del CEO	no data
Participación del CEO	n/a
Permanencia media de la dirección	1.2yrs
Promedio de permanencia en la Junta Directiva	2.7yrs

Actualizaciones recientes de la dirección

Recent updates

CEO

Chris Coughlin (53 yo)

no data

Permanencia

UK£37,000

Compensación

Dr. Christina M. Coughlin, also known as Chris, BS, MD, PH D., was Head of Research and Development of Avacta Group Plc from February 1, 2024 and serves as its Chief Executive Officer from May 01, 2024 and...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	no data	UK£37.00k	sin datos
Tony Gardiner	CFO, Company Secretary & Executive Director	8.3yrs	UK£273.00k	0.0023% £ 4.6k
Emma Wright	Group In-House Counsel	no data	sin datos	sin datos
Michael Vinegrad	Group Communications Director	3.3yrs	sin datos	sin datos
R. Slater	Chief Operating Officer of Diagnostics	7.8yrs	UK£69.00k	sin datos
Matt Johnson	Chief Scientific Officer of Diagnostics	3.3yrs	sin datos	sin datos
David Wilson	Chief Commercial Officer of Diagnostics	1.3yrs	sin datos	sin datos
Karen Harrison	Chief Operating Officer of Therapeutics Division	1.2yrs	sin datos	sin datos
Anne McGurk	Joint Managing Director of Launch Diagnostics	1.1yrs	sin datos	sin datos
Ian Jones	Joint Managing Director of Launch Diagnostics	1.1yrs	sin datos	sin datos
Simon Bennett	Chief Business Officer of Therapeutics	less than a year	sin datos	sin datos
Sebastien Goenen	Chief Operating Officer of Coris BioConcept	1.2yrs	sin datos	sin datos

1.2yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de AVCT.F no se considera experimentado ( 1.3 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Christina Coughlin	CEO, Interim Chief Medical Officer and Director	2.2yrs	UK£37.00k	sin datos
Tony Gardiner	CFO, Company Secretary & Executive Director	8.3yrs	UK£273.00k	0.0023% £ 4.6k
Trevor Nicholls	Independent Non-Executive Director	10.8yrs	UK£40.00k	0.030% £ 60.4k
Eliot Forster	Independent Non-Executive Chairman	5.9yrs	UK£100.00k	0.048% £ 95.3k
Shaun Chilton	Non-Executive Director	less than a year	sin datos	sin datos
Mark A. Goldberg	Independent Non-Executive Director	2.8yrs	UK£45.00k	sin datos
Paul Fry	Independent Non-Executive Director	4.3yrs	UK£40.00k	sin datos
James Spicer	Member of Scientific Advisory Board	2.7yrs	sin datos	sin datos
Krishna Komanduri	Member of Scientific Advisory Board	2.7yrs	sin datos	sin datos
Stephane Champiat	Member of Scientific Advisory Board	2.7yrs	sin datos	sin datos

2.7yrs

Permanencia media

57yo

Promedio de edad

Junta con experiencia: La junta directiva de AVCT.F no se considera experimentada (2.7 años de permanencia promedio), lo que sugiere una nueva junta directiva.

Avacta Group Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group Plc Announces Management Changes

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Recent updates

Avacta Group plc Announces Successful Completion of First Cohort and Dosing of Three Patients of the Second Cohort in Arm 2 of Avacta's Ava6000 Phase 1 Trial

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Announces Chief Executive Officer Changes

Avacta Group plc Reports Data from the Ongoing Phase 1 Clinical Trial of AVA6000 At the AACR Annual Meeting

Avacta Group Plc Announces Update on AVA6000 Phase 1a Clinical Trial Progress

Avacta Group Plc has completed a Follow-on Equity Offering in the amount of £5.448474 million.

Avacta Group Plc has filed a Follow-on Equity Offering in the amount of AUD 20.560243 million.

Avacta Group plc Announces Appointment of Christina Coughlin as Head of Research and Development and Resignation of Fiona Mclaughlin as Chief Scientific Officer

Avacta Group plc Appoints Simon Bennett as Chief Business Officer of the Therapeutics Division

Avacta Group plc Provides Detailed Pre-Clinical, Clinical and Pharmacokinetic Data from the Phase 1A Dose Escalation Study

Avacta Group Plc Announces Management Changes

Avacta Group plc Announces Successful Completion of ALS-6000-101 Sixth Dose Escalation

Avacta Group Plc to Report First Half, 2023 Results on Sep 28, 2023

Avacta Announces Successful Completion of Fifth Dose Escalation in Ava6000 Phase 1 Clinical Study

Avacta Group plc Appoints Shaun Chilton to the Board as Non-Executive Director

Avacta Group Plc (AIM:AVCT) acquired Unknown minority stake in AffyXell Therapeutics Co., Ltd. from Daewoong pharmaceutical Co.,Ltd (KOSE:A069620).

Avacta Group Plc, Annual General Meeting, Jun 28, 2023

Avacta Group plc acquired Coris Bioconcept SRL for £10.4 million.

Avacta Group plc Announces Successful Completion of Fourth Dose Escalation in AVA6000 Phase 1 Clinical Study

Avacta Group Plc (AIM:AVCT) conditionally agreed to acquire Launch Diagnostics Holdings Limited for £37 million.

Avacta Group Plc to Report First Half, 2022 Results on Sep 29, 2022

Avacta Group plc Announces Phase I Study of AVA6000 Advances to Fourth Cohort

Avacta Group Plc announced that it has received funding

Avacta Group Plc Announces Second Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group Plc, Annual General Meeting, Jun 23, 2022

Avacta Group Plc Relocates its Therapeutics Division to New Headquarters at Scale Space, in Imperial College's White City Campus, London

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Group Plc to Report Fiscal Year 2021 Results on Apr 06, 2022

Avacta Announces Dose Escalation in the Phase I Clinical Study of AVA6000 Pro-Doxorubicin

Avacta Group plc Selects Second Pre|Cision™ Pro-Drug Candidate for Development

Avacta Group plc Provides Update on AffiDX SARS-CoV-2 Antigen Lateral Flow Test and Detection of the Omicron Variant

Avacta Group Plc Announces AffiDX® SARS-CoV-2 Antigen Lateral Flow Test Has Received A CE Mark for Use as A Consumer Self-Test in the UK and EU

Avacta Group Plc Announces AffiDx® SARS-CoV-2 Antigen Lateral Flow Test Detects the Omicron Variant

Avacta Group plc Announces US Food and Drug Administration Approval of IND Application for AVA6000

Avacta Group Plc Announces Pre-Clinical Development Milestone in LG Chem Life Sciences Partnership

Avacta Group plc Provides Update on AffiDX Lateral Flow Test

Avacta Announces Registration of its AffiDX SARS-CoV-2 Antigen Lateral Flow Test in EU

MHRA Confirms Registration of Avacta’s Affidx® SARS-CoV-2 Antigen Lateral Flow Test

Avacta Group plc Provides an Update on Lateral Flow Test Regulatory Submissions

Avacta Signs Diagnostic Licensing Deal with Biokit

Avacta Group plc Announces its AffiDX SARS-CoV-2 Rapid Antigen Lateral Flow Test Detects the Dominant New Variants of the Coronavirus

Avacta Announces Phase 1 Clinical Trial Authorisation (CTA) for AVA6000 Approved by MHRA

Avacta Group plc Announces Results of Initial Evaluation of Sars-Cov-2 Lateral Flow Antigen Test with Clinical Samples

Avacta Group plc Enters into Commercial Partnership with Mologic Ltd

Avacta Announces Collaboration Agreement with Bruker

Avacta Group plc Announces License Agreement with Point Biopharma Inc

Avacta Submits Clinical Trial Application for Ava6000 Pro-Doxorubixin

Gamma Biosciences Announces Strategic Licensing Agreement by Astrea Bioseparations for Advanced Application of Avacta Affimer® Reagent Technology

Avacta Group plc Announces Significant Progress in Development of a Highly Scalable Manufacturing Process for Lateral Flow SARS-CoV-2 Antigen Test

Avacta Group Plc Launches SARS-CoV-2 BAMS Research Test

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad